Allosteric modulation of G protein-coupled receptors.

The past decade has witnessed a significant growth in the identification of allosteric modulators of G protein-coupled receptors (GPCRs), i.e., ligands that interact with binding sites that are topographically distinct from the orthosteric site recognized by the receptor's endogenous agonist. Because of their ability to modulate receptor conformations in the presence of orthosteric ligand, allosteric modulators can "fine-tune" classical pharmacological responses. This is advantageous in terms of a potential for engendering greater GPCR subtype-selectivity, but represents a significant challenge for detecting and validating allosteric behaviors. Although allosteric sites need not have evolved to accommodate endogenous ligands, there are a number of examples of where such modulators have been shown to contribute to physiological or pathophysiological processes. Studies are also beginning to unravel the structural basis of allosteric modulation of GPCRs. It remains to be determined whether such modulation represents interactions within monomers versus across dimers.

[1]  P. Conn,et al.  A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators , 2006, Molecular Pharmacology.

[2]  K. Mohr,et al.  Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.

[3]  Anandan Palani,et al.  Interaction of small molecule inhibitors of HIV-1 entry with CCR5. , 2006, Virology.

[4]  Yasushi Tojo,et al.  Structural and Molecular Interactions of CCR5 Inhibitors with CCR5* , 2006, Journal of Biological Chemistry.

[5]  M. Parmentier,et al.  Allosteric Modulation of Binding Properties between Units of Chemokine Receptor Homo- and Hetero-Oligomers , 2006, Molecular Pharmacology.

[6]  L. Sterin‐Borda,et al.  Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients , 2006, Neuropharmacology.

[7]  Lila M Gierasch,et al.  The changing landscape of protein allostery. , 2006, Current opinion in structural biology.

[8]  K. Neve,et al.  Identification of a Zn2+-binding site on the dopamine D2 receptor. , 2006, Biochemical and biophysical research communications.

[9]  U. Holzgrabe,et al.  Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. , 2006, Journal of medicinal chemistry.

[10]  Andreas Mühlemann,et al.  Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. , 2006, European journal of pharmacology.

[11]  C. Langmead,et al.  Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist , 2006, Molecular Pharmacology.

[12]  T. Schwartz,et al.  Ago-Allosteric Modulation and Other Types of Allostery in Dimeric 7TM Receptors , 2006, Journal of receptor and signal transduction research.

[13]  P. Sexton,et al.  GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.

[14]  J. Cryan,et al.  A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Niznik,et al.  Modulation of Agonist Binding to Human Dopamine Receptor Subtypes by l-Prolyl-l-leucyl-glycinamide and a Peptidomimetic Analog , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  U. Holzgrabe,et al.  Atypical Muscarinic Allosteric Modulation: Cooperativity between Modulators and Their Atypical Binding Topology in Muscarinic M2 and M2/M5 Chimeric Receptors , 2005, Molecular Pharmacology.

[17]  T. Kenakin New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[18]  F. Ehlert Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[19]  A. Christopoulos,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.

[20]  A. IJzerman,et al.  Allosteric modulators affect the internalization of human adenosine A1 receptors. , 2005, European journal of pharmacology.

[21]  T. Schwartz,et al.  Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. , 2005, Molecular Endocrinology.

[22]  Xi-Ping Huang,et al.  Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide , 2005, Molecular Pharmacology.

[23]  T. Durroux Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. , 2005, Trends in pharmacological sciences.

[24]  C. Goudet,et al.  Allosteric functioning of dimeric class C G‐protein‐coupled receptors , 2005, The FEBS journal.

[25]  S. Swillens,et al.  Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity , 2005, The EMBO journal.

[26]  R. Abagyan,et al.  Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.

[27]  T. Kenakin,et al.  The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.

[28]  C. Lindsley,et al.  A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  S. Hoare,et al.  Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.

[30]  P. Sexton,et al.  Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators , 2005, Journal of Pharmacology and Experimental Therapeutics.

[31]  Johan Hoebeke,et al.  Modulation of the M2 Muscarinic Acetylcholine Receptor Activity with Monoclonal Anti-M2 Receptor Antibody Fragments* , 2004, Journal of Biological Chemistry.

[32]  A. Christopoulos,et al.  Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors. , 2004, Biochemical pharmacology.

[33]  J. Wells,et al.  Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.

[34]  J. Banères,et al.  Cooperative Conformational Changes in a G-protein-coupled Receptor Dimer, the Leukotriene B4 Receptor BLT1* , 2004, Journal of Biological Chemistry.

[35]  D. A. Annis,et al.  A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. , 2004, Journal of the American Chemical Society.

[36]  D. S. Hage,et al.  Quantitative analysis of allosteric drug-protein binding by biointeraction chromatography , 2004, Nature Biotechnology.

[37]  H. Mitsuya,et al.  Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.

[38]  Terry Kenakin,et al.  Allosteric modulators: the new generation of receptor antagonist. , 2004, Molecular interventions.

[39]  Irina D Pogozheva,et al.  Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. , 2004, Biochemistry.

[40]  L. Prézeau,et al.  The Heptahelical Domain of GABAB2 Is Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABAB Receptor* , 2004, Journal of Biological Chemistry.

[41]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors. , 2004, Current pharmaceutical design.

[42]  P. Sexton,et al.  Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[43]  A. Christopoulos,et al.  Investigation of the Interaction of a Putative Allosteric Modulator, N-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) Methanamine Hydrobromide (SCH-202676), with M1 Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[44]  M. Shlesinger,et al.  Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators. , 2004, Biophysical journal.

[45]  R. Wolf,et al.  Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.

[46]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[47]  S. Urwyler,et al.  Selected amino acids, dipeptides and arylalkylamine derivatives do not act as allosteric modulators at GABAB receptors. , 2004, European journal of pharmacology.

[48]  E. Borda,et al.  Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren's syndrome , 1996, Molecular and Cellular Biochemistry.

[49]  S. Lazareno,et al.  Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. , 2004, Molecular pharmacology.

[50]  Francine Acher,et al.  Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Rognan,et al.  Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.

[52]  J. Linden,et al.  Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. , 2003, Molecular pharmacology.

[53]  Arthur Christopoulos,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.

[54]  S. Urwyler,et al.  N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of γ-Aminobutyric AcidB Receptor Function , 2003, Journal of Pharmacology and Experimental Therapeutics.

[55]  L. Bristow,et al.  Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. , 2003, Molecular pharmacology.

[56]  Philippe Billiald,et al.  scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the β2-Adrenergic Receptor* , 2003, Journal of Biological Chemistry.

[57]  E. Clercq The bicyclam AMD3100 story , 2003, Nature Reviews Drug Discovery.

[58]  John Ellis,et al.  Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. , 2003, Molecular pharmacology.

[59]  M. Shlesinger,et al.  Cellular and Behavioral Effects of D2 Dopamine Receptor Hydrophobic Eigenmode-Targeted Peptide Ligands , 2003, Neuropsychopharmacology.

[60]  Claudio N. Cavasotto,et al.  Structure‐based identification of binding sites, native ligands and potential inhibitors for G‐protein coupled receptors , 2003, Proteins.

[61]  Xavier Langlois,et al.  [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. , 2003, Molecular pharmacology.

[62]  Thomas P. Sakmar,et al.  Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.

[63]  Kenneth A Jacobson,et al.  Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. , 2003, Molecular pharmacology.

[64]  J. Kew,et al.  Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.

[65]  N. Ling,et al.  Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. , 2003, Molecular Pharmacology.

[66]  B. Kobilka,et al.  Identification of an Allosteric Binding Site for Zn2+on the β2 Adrenergic Receptor* , 2003, The Journal of Biological Chemistry.

[67]  T. Schwartz,et al.  Metal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 Receptors* , 2002, The Journal of Biological Chemistry.

[68]  S. Lazareno,et al.  Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. , 2002, Molecular pharmacology.

[69]  K. Jacobson,et al.  Identification of Acidic Residues in the Extracellular Loops of the Seven-transmembrane Domain of the Human Ca2+ Receptor Critical for Response to Ca2+ and a Positive Allosteric Modulator* , 2002, The Journal of Biological Chemistry.

[70]  S. Foord Receptor classification: post genome. , 2002, Current opinion in pharmacology.

[71]  U. Hacksell,et al.  Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.

[72]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[73]  W. Sadee,et al.  Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.

[74]  J. Longmore,et al.  Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists* 210 , 2002, The Journal of Biological Chemistry.

[75]  L. Limbird,et al.  G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. , 2002, Cellular signalling.

[76]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[77]  A. Christopoulos Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[78]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[79]  S. Rees,et al.  GPCR drug discovery through the exploitation of allosteric drug binding sites. , 2002, Receptors & channels.

[80]  K. Mohr,et al.  Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. , 2002, Molecular pharmacology.

[81]  S. Urwyler,et al.  Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. , 2001, Molecular pharmacology.

[82]  K. Jacobson,et al.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. , 2001, Molecular pharmacology.

[83]  J. Kemp,et al.  Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[84]  A. Krejci,et al.  Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. , 2001, Molecular pharmacology.

[85]  J. Gleason,et al.  Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. , 2001, The Journal of pharmacology and experimental therapeutics.

[86]  E. De Clercq,et al.  Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.

[87]  J. Adelman,et al.  ATP-dependent Activation of the Intermediate Conductance, Ca2+-activated K+ Channel, hIK1, Is Conferred by a C-terminal Domain* , 2001, The Journal of Biological Chemistry.

[88]  Michel Bouvier,et al.  Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.

[89]  D. Sibley,et al.  The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. , 2001, The Journal of pharmacology and experimental therapeutics.

[90]  A. IJzerman,et al.  Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. , 2001, Biochemical pharmacology.

[91]  F. Fahrenholz,et al.  Molecular modelling study of the role of cholesterol in the stimulation of the oxytocin receptor. , 2001, Acta biochimica Polonica.

[92]  D. Hall,et al.  Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. , 2000, Molecular pharmacology.

[93]  F. Gasparini,et al.  The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.

[94]  E. Freire,et al.  Can allosteric regulation be predicted from structure? , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[95]  S. Lazareno,et al.  Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. , 2000, Molecular pharmacology.

[96]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[97]  E. Brown,et al.  L-amino acid sensing by the extracellular Ca2+-sensing receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[98]  L. Prézeau,et al.  Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. , 2000, Molecular pharmacology.

[99]  P B Hedlund,et al.  Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. , 1999, Biochemical pharmacology.

[100]  J. Ellis,et al.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.

[101]  A. Christopoulos,et al.  The assessment of antagonist potency under conditions of transient response kinetics. , 1999, European journal of pharmacology.

[102]  R. Ranganathan,et al.  Evolutionarily conserved pathways of energetic connectivity in protein families. , 1999, Science.

[103]  R. Mobini,et al.  Probing the immunological properties of the extracellular domains of the human beta(1)-adrenoceptor. , 1999, Journal of autoimmunity.

[104]  R. Mishra,et al.  Modulation of agonist stimulated adenylyl cyclase and GTPase activity by l-pro-l-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes , 1999, Neuroscience Letters.

[105]  G. Wallukat,et al.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. , 1999, The Journal of clinical investigation.

[106]  M. Maccoss,et al.  Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.

[107]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[108]  G. Fillion,et al.  Molecular, Cellular and Physiological Characteristics of 5‐HT‐Moduline, a Novel Endogenous Modulator of 5‐HT1B Receptor Subtype , 1998, Annals of the New York Academy of Sciences.

[109]  A. Berra,et al.  Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. , 1998, Current eye research.

[110]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[111]  J. Garrett,et al.  Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. , 1998, Molecular pharmacology.

[112]  Hans H. Zingg,et al.  Inhibition of oxytocin receptor function by direct binding of progesterone , 1998, Nature.

[113]  M F Balandrin,et al.  Calcimimetics with potent and selective activity on the parathyroid calcium receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[114]  A. Christopoulos,et al.  ALLOSTERIC INTERACTIONS AT MUSCARINIC CHOLINOCEPTORS , 1998, Clinical and experimental pharmacology & physiology.

[115]  G. Wallukat,et al.  Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. , 1998, European journal of biochemistry.

[116]  M. Neal,et al.  Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[117]  G. Gimpl,et al.  Cholesterol as modulator of receptor function. , 1997, Biochemistry.

[118]  A. Christopoulos,et al.  Application of an Allosteric Ternary Complex Model to the Technique of Pharmacological Resultant Analysis , 1997, The Journal of pharmacy and pharmacology.

[119]  D. Sibley,et al.  Zinc Allosterically Modulates Antagonist Binding to Cloned D1 and D2 Dopamine Receptors , 1997, Journal of neurochemistry.

[120]  E. Borda,et al.  Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[121]  E. Kostenis,et al.  KOSTENIS AND MOHR REPLY : COMPOSITE ACTION OF ALLOSTERIC MODULATORS ON LIGAND BINDING , 1996 .

[122]  S. Hoare,et al.  Regulation of D2 dopamine receptors by amiloride and amiloride analogs. , 1996, Molecular pharmacology.

[123]  R. Hen,et al.  5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. , 1996, Molecular pharmacology.

[124]  S. Lazareno,et al.  Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.

[125]  A. Strosberg,et al.  Characterization of Pharmacologically Active Anti‐Peptide Antibodies Directed Against the First and Second Extracellular Loops of the Serotonin 5‐HT1A Receptor , 1995, Journal of neurochemistry.

[126]  S. Lazareno,et al.  Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.

[127]  A. Christopoulos,et al.  Assessment of the allosteric interactions of the bisquaternary heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at M1 and M2 muscarine receptors. , 1994, Molecular pharmacology.

[128]  M. Eck,et al.  Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. , 1994, Molecular pharmacology.

[129]  A. Fryer,et al.  Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. , 1992, The Journal of clinical investigation.

[130]  J. Ellis,et al.  Two allosteric modulators interact at a common site on cardiac muscarinic receptors. , 1992, Molecular pharmacology.

[131]  D Rodbard,et al.  Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.

[132]  E. Borda,et al.  Distribution of Antibodies against β-Adrenoceptors in the Course of Human Trypanosoma cruzi Infection , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[133]  J. Fergus,et al.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[134]  P. Portoghese Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. , 1989, Trends in pharmacological sciences.

[135]  F. Ehlert,et al.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.

[136]  F. Ehlert The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. , 1985, Molecular pharmacology.

[137]  E. Borda,et al.  A circulating IgG in Chagas' disease which binds to beta-adrenoceptors of myocardium and modulates their activity. , 1984, Clinical and experimental immunology.

[138]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[139]  J. Changeux,et al.  Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.

[140]  B. Katz,et al.  A study of the ‘desensitization’ produced by acetylcholine at the motor end‐plate , 1957, The Journal of physiology.

[141]  J. Wyman,et al.  The problem of the heme interactions in hemoglobin and the basis of the bohr effect , 1951 .

[142]  Christian Bohr,et al.  Ueber einen in biologischer Beziehung wichtigen Einfluss, den die Kohlensäurespannung des Blutes auf dessen Sauerstoffbindung übt1 , 1904 .